Pressure Ulcer, Buttock Clinical Trial
Official title:
A Randomized, Non-blind Study of TurnCare's Q-2 System on the Sacral Pressure Ulcer Prevention in High Risk Patients at St. Vincent's Medical Center
| Verified date | April 2017 |
| Source | TurnCare Inc. |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This is a non-blind randomized clinical trial to determine the efficacy of the TurnCare Q2 System for the prevention of sacral region (sacral, coccygeal, and buttocks) pressure ulcers. TurnCare Q2 System has 2 main components: 1. An Inflatable Skin Perfusion Enhancement Surface and 2. An Adaptive Pressure Controller. The Skin Perfusion Enhancement Surface has a patented design that accommodate human anatomy in the sacra region. The Adaptive Pressure Controller is powered by APSAR technology that provides patient specific pressure relieve in the sacral region.
| Status | Active, not recruiting |
| Enrollment | 431 |
| Est. completion date | May 1, 2017 |
| Est. primary completion date | October 31, 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Subjects have a Braden Score of 16 or less without pre-existing sacral region pressure ulcers and are not subject to exclusion criteria Exclusion Criteria: - Pre-existing sacral region pressure ulcer - Refusal to participate - Inability to obtain consent - Pregnancy - Age less than 18 years - Mentally challenged - Prisoner - Unstable spine or pelvic injuries - Recent surgical skin graft to sacral area - Weight > 400 lbs. - Psychiatric condition |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| TurnCare Inc. |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Incidence of hospital acquired sacral region pressure ulcers in treatment and control groups. | Rate of hospital acquired sacral pressure ulcer occurrence measurred in metrics named "number of incidences in 1,000 patient days." | Up to 10 weeks. Average of 4 weeks from enrollment. |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04266808 -
Interactive Telehealth for Wheelchair Users
|
N/A | |
| Completed |
NCT04168450 -
Evaluation of Wheelchair In-Seat Activity Tracker
|
N/A | |
| Completed |
NCT04890678 -
The Use of a Fully Automated Pulsating Support System (CuroCell® A4 CX20) in Pressure Ulcer Prevention and Treatment
|
N/A |